Piper Sandler analyst Joseph Catanzaro assumed coverage of Gilead with an Overweight rating and $105 price target. The company’s Q1 performance highlighted the resilience of its core virology commercial business alongside an "increasingly more compelling" oncology portfolio, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GILD:
